ArticleBMC public health2026
A retrospective cohort study and spatial analysis of climate and community-level determinants of respiratory syncytial virus notifications among Queensland infants, prior to the introduction of the RSV mother and infant protection program (RSV-MIPP) immunisation initiative.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a highly infectious seasonal respiratory pathogen and a major cause of morbidity in young children. In Australia, RSV is the leading cause of hospitalisation for bronchiolitis and pneumonia among children aged < 2 years, with the highest severity observed in infants aged < 6 months. RSV became a nationally notifiable condition in July 2021, and the national RSV Mother and Infant Protection Program (RSV-MIPP) commenced in February 2024. Baseline data on RSV incidence and its determinants are needed to evaluate the effectiveness of the program and identify populations at greatest risk.
methodsRetrospective cohort study with spatial analysis of all RSV notifications among children aged < 2 years residing in the state of Queensland, Australia between 1 January 2022 and 31 December 2023. Data were obtained from the Queensland Notifiable Conditions System. Incidence rates were calculated by exact age in infant months, year, epidemiological week, and climate zone, using all resident children as the denominator population. Spatial cluster analysis methods identified postcode areas with high incidence, and associations in climate zones, and community-level characteristics (remoteness, socioeconomic status, average number of children per family household).
results18,683 notifications were recorded among children aged < 2 years between 2022−2023 (79.7 per 1,000 in 2022; 84.8 per 1,000 in 2023). Incidence was consistently higher among 1-month-olds (96.6 per 1,000) and 12-month-olds (96.7 per 1,000). Compared to tropical climates, incidence was higher in temperate (aRR 1.26, 95% CI 1.13−1.41) and arid/semi-arid zones (aRR 1.18, 95% CI 1.00−1.38), with differences in timing and magnitude of epidemics between climate zones. Higher incidence was observed in areas with larger family sizes (aRR 1.39, 95% CI 1.13−1.72). Remoteness was associated with lower incidence (aRR 0.89, 95% CI 0.87−0.92).
conclusionsIn Queensland, children living in areas with larger family sizes and temperate or arid/semi-arid climates experienced higher incidence of RSV infections. Lower recorded incidence in remote areas may reflect undertesting or lower-case ascertainment. Future RSV-MIPP strategies should prioritise climatic and community-level determinants through targeted outreach and enhanced surveillance to facilitate equitable access. There is an urgent need for new strategies to protect infants aged > 6 months, when protection from maternal vaccination and birth dose therapeutics wanes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.